This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Covidien Launches Two Enhanced LigaSure™ Vessel Sealing Products At American College Of Surgeons Clinical Congress 2013

Covidien (NYSE: COV), a leading global provider of healthcare products, is strengthening its vessel sealing portfolio with the launch of two advanced energy devices, the LigaSure Impact™ curved large jaw open sealer/divider LF4318 and LigaSure™ blunt tip laparoscopic sealer/divider LF1637. The two products offer improvements in handling, control and performance, as compared to their predecessor devices. LigaSure products used with the ForceTriad™ energy platform utilize TissueFect™ sensing technology, a proprietary Covidien control system designed to precisely manage energy delivery, creating a range of options for desired tissue effect.

“Around the world, Covidien’s LigaSure devices are a trusted and valued product portfolio in the operating room. LigaSure vessel sealing instruments already are used in millions of surgical procedures and we continue to innovate to enhance our products,” said Chris Barry, President of Advanced Surgical Technologies, Covidien. “Since introduction in 1998, our LigaSure devices, combined with TissueFect sensing technology, have set the standard in vessel sealing.”

The LigaSure Impact device, featuring a curved, large jaw open sealer/divider, offers improved visibility in the surgical field, more intuitive jaw positioning and enhanced ergonomics for a better surgical experience. The LigaSure blunt tip laparoscopic sealer/divider has contoured tips for improved dissection, better handling and a more compact, ergonomic handle for greater comfort and control for various hand sizes.

Both the LigaSure Impact and blunt tip devices received U.S Food and Drug Administration 510(k) clearance earlier this year and are ideally suited for colorectal, general, gynecologic, urologic and thoracic surgery.

About LigaSure and TissueFect

With more than eight million procedures completed worldwide, LigaSure technology is supported by an ever-growing body of evidence-based research, now totaling well over 300 published peer-reviewed studies.

LigaSure tissue fusion in the ForceTriad energy platform, has faster fusion cycles, more flexible fusion zones and less desiccation than the original LigaSure generator. TissueFect sensing technology monitors changes in tissue 3,333 times a second and adjusts energy output accordingly to deliver the appropriate amount of energy for the desired tissue effect.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs